• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PVLA

    Palvella Therapeutics Inc.

    Subscribe to $PVLA
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Palvella Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/9/2025$50.00Buy
    Chardan Capital Markets
    3/26/2025$45.00Buy
    Stifel
    3/7/2025$50.00Sector Outperform
    Scotiabank
    2/20/2025$39.00Buy
    Canaccord Genuity
    2/5/2025$44.00Buy
    TD Cowen
    12/26/2024$38.00Buy
    H.C. Wainwright
    12/18/2024Overweight
    Cantor Fitzgerald
    See more ratings

    Palvella Therapeutics Inc. SEC Filings

    See more
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      6/11/25 4:05:57 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Palvella Therapeutics Inc.

      10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      5/15/25 7:45:33 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      5/15/25 7:31:32 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Palvella Therapeutics Inc.

      DEFA14A - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      4/30/25 4:08:36 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Palvella Therapeutics Inc.

      DEF 14A - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      4/30/25 4:05:59 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Palvella Therapeutics Inc.

      10-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      3/31/25 7:51:15 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      3/31/25 7:32:24 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      3/4/25 8:00:33 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Palvella Therapeutics Inc.

      S-8 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      2/18/25 4:39:55 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Palvella Therapeutics Inc.

      424B3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      1/17/25 4:07:37 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      4/10/25 7:06:12 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jenkins George M bought $51,720 worth of shares (4,000 units at $12.93), increasing direct ownership by 2% to 180,671 units (SEC Form 4)

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      12/19/24 10:23:28 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

      WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. Annual Russell indexes reconstitution captures the 3,000 largest US stocks, ranking them by total market capitalization. Membership in the

      6/30/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

      Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the successful completion of SELVA, a Phase 3 trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatme

      6/23/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

      New intellectual property builds on Palvella's multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No. 12,329,748 for claims related to the Company's lead product candidate QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin

      6/18/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

      FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts Up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data from SELVA expected in the first quarter of 2026 WAYNE, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing and commercializing novel therapies for serious, rare genetic skin diseases with no U.S. Food and Drug Administration (FDA)-approved treatments, today announced it has received the initial proceeds from a previously announced grant from the FDA Office of Orphan Products Development.

      6/9/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

      Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

      5/27/25 8:00:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of Ma

      5/15/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" se

      5/8/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

      WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that the Company will ring the opening bell at the Nasdaq Stock Market (Nasdaq) on Monday, May 12, 2025 in New York City. Wes Kaupinen, Founder and Chief Executive Officer, will be joined by members of the Palvella management team, Board of Directors, investors, advisors, and guests at the ceremony which wi

      5/5/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

      Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation Poster to be presented on Thursday, May 8, 2025, 4:30-6:00 pm PT WAYNE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-appr

      4/23/25 4:15:00 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

      Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issue

      4/22/25 7:29:59 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Palvella Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $50.00

      4/9/25 7:50:47 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Palvella Therapeutics with a new price target

      Stifel initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $45.00

      3/26/25 7:50:34 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Palvella Therapeutics with a new price target

      Scotiabank initiated coverage of Palvella Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

      3/7/25 8:18:07 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Palvella Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $39.00

      2/20/25 7:05:42 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Palvella Therapeutics with a new price target

      TD Cowen initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $44.00

      2/5/25 7:03:25 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Palvella Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $38.00

      12/26/24 7:16:05 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Palvella Therapeutics

      Cantor Fitzgerald initiated coverage of Palvella Therapeutics with a rating of Overweight

      12/18/24 8:31:22 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wessel Tadd S.

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 8:00:08 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kiritsy Christopher P

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:56 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Jenkins George M

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:46 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heron Elaine J

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:36 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Davis Todd C

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/11/25 7:59:24 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Kline Ashley Hartmann

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/3/25 9:15:01 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kline Ashley Hartmann

      3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      6/3/25 9:08:23 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      4/10/25 7:06:12 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by President and CEO Kaupinen Wes

      4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      2/10/25 6:25:31 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Scientific Officer Martini Jeffrey S

      4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      2/10/25 6:00:29 PM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

      Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

      5/27/25 8:00:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Palvella Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of Ma

      5/15/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

      WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" se

      5/8/25 7:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

      WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" sect

      3/18/25 8:30:00 AM ET
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care